Although these inhibitors exhibit pronounced anti-cancer effects in K-Ras G12C tumor mice models and in clinical trials (Canon et al, 2019; Hallin et al, 2020), the K-Ras G12C mutation is found only in ∼3% pancreatic, ∼4% colorectal, and ∼13% of lung cancers that harbor any oncogenic mutations in K-Ras, making it effective against only a small subset of the K-Ras-driven cancers (Cox et al, 2014; Prior et al, 2020). Here, KRAS is linked to neoplasm.